CM Hospitalar (VVEO3) Q4 2024 earnings summary

Executive summary

• Achieved significant operational integration after over 25 acquisitions since 2017, consolidating legal entities and reducing ERP systems, with a focus on system and process unification in 2023-2024.

• Shifted strategy from rapid growth to operational execution, efficiency, and profitability recovery for 2025, prioritizing cash generation and margin improvement.

• Leadership team restructured, with new executives in key roles, centralized governance, and the addition of independent directors and a Strategy Committee.

• Revenue grew 4.5% year-over-year to R$11.58 billion, with growth in hospitals/clinics and vaccines, but declines in services and stable performance in retail.

• Net loss of R$1.42 billion, driven by non-recurring items, impairments, and provisions, compared to a net profit of R$360 million in 2023.

Financial highlights

• Net revenue for 2024 was R$11,583.4 million, up 4.5% from 2023; Q4 revenue was R$2,936.8 million, up 1.1% year-over-year.

• Adjusted EBITDA for 2024 was R$652.1 million, down 29.7% year-over-year, with a margin of 5.6%.

• Free cash flow turned positive at R$206.2 million in 2024, reversing a negative R$892.5 million in 2023.

• Adjusted net loss for 2024 was R$90.4 million, compared to an adjusted net profit of R$253 million in 2023.

• ROIC for 2024 was 10.9%, down from 14.7% in 2023.

Outlook and guidance

• 2025 will focus on execution, operational efficiency, cost reduction, margin recovery, cash generation, and deleveraging, with profitability prioritized over volume growth.

• Capex for 2025 is planned at R$150 million, down from over R$300 million in 2023.

• Action plans underway to attract new clients, expand partnerships, and improve profitability in underperforming segments.